Global Radiotherapy Induced Oral Mucositis Treatment Strategies 2025, Forecast To 2034
26 Mar, 2025
How Has the Radiotherapy Induced Oral Mucositis Treatment Market Evolved Historically and What is its Current Size?
The radiotherapy induced oral mucositis treatment market has seen considerable growth due to a variety of factors.
• The market size for the treatment of oral mucositis caused by radiotherapy has exhibited robust growth in recent years. It is projected to expand from $1.76 billion in 2024 to $1.85 billion in 2025, at a compound annual growth rate (CAGR) of 5.5%.
The growth observed during the historic period can be attributed to factors such as the global rise in cancer rates, increased awareness about oral mucositis, a growing number of head and neck cancer incidents, the expansion of the healthcare infrastructure, and the escalating demand for supportive care solutions.
What is the Forecasted Market Size and CAGR for the Radiotherapy Induced Oral Mucositis Treatment Market?
The radiotherapy induced oral mucositis treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market for treatments combating oral mucositis caused by radiotherapy is expected to experience significant growth in the upcoming years, expanding to a value of $2.27 billion in 2029 with a CAGR of 5.2%.
This growth during the forecast period is due to factors such as the increased use of regenerative medicine, the increasing occurrence of radiotherapy, higher cases of chronic diseases, the broadening of telehealth services, and the rising demand for home-based care solutions. The forecast period also expects major trends like the advancement of intensity modulated radiotherapy techniques, the emergence of targeted therapies, the integration of telemedicine, the rise of personalized medicine approaches, and improvements in imaging techniques.
What Key Factors and Trends Are Driving The Growth Radiotherapy Induced Oral Mucositis Treatment Market?
The escalating worldwide incidence of cancer is projected to propel the growth of the market for radiotherapy induced oral mucositis treatment. Cancer, a disease marked by the unchecked expansion and proliferation of abnormal cells that can infiltrate nearby tissues and organs, is driven by genetic changes influenced by environmental factors and lifestyle habits. The surge in global cancer prevalence is predominantly attributed to aging populations, lifestyle choices like tobacco use, obesity, and alcohol consumption, as well as environmental conditions like air pollution. The purpose of Radiotherapy Induced Oral Mucositis Treatment is to alleviate the painful side effects of mucosal damage caused by radiotherapy in cancer patients, which allows them to better handle treatment, maintain their dietary intake, and ultimately enhance their quality of life during cancer therapy. For example, a report by Macmillan Cancer Support, a charity-based organization in the UK, indicated that over 3 million people were living with cancer in the UK in August 2024. This number is estimated to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Hence, the escalating global incidence of cancer is a significant determinant for the growth of the radiotherapy induced oral mucositis treatment market.
What Are The Market Segments In The Radiotherapy Induced Oral Mucositis Treatment Market?
The radiotherapy induced oral mucositis treatment market covered in this report is segmented –
1) By Drug Class: Antibiotics, Antifungal, Anti-Inflammatory, Anti-Neoplastic
2) By Treatment Type: Topical Agents, Systemic Agents, Medical Devices
3) By Radiotherapy Type: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Brachytherapy, Proton Therapy, Stereotactic Radiosurgery (SRS), Other Radiotherapy Type
4) By Severity Type: Mild Oral Mucositis, Moderate Oral Mucositis, Severe Oral Mucositis (SOM)
5) By End User: Hospitals, Oncology Centres, Research Institutes, Dental Clinics
Subsegments:
1) By Antibiotics: Topical Antibiotics, Oral Antibiotics
2) By Antifungal: Topical Antifungals, Oral Antifungals
3) By Anti-inflammatory: Corticosteroids, Non-steroidal Anti-inflammatory Drugs (NSAIDs)
4) By Anti-neoplastic: Chemotherapy Agents, Targeted Therapy Agents
What Trends Are Reshaping The Future Of The Radiotherapy Induced Oral Mucositis Treatment Market?
Leading businesses in the oral mucositis treatment market, brought on by radiotherapy, are concentrating their efforts on crafting innovative therapeutic solutions such as low-level laser therapy to boost healing, decrease discomfort, and enhance patient prognosis during cancer treatment. Low-level laser treatment, also referred to as cold laser treatment or photobiomodulation, is a non-invasive procedure that utilizes low-intensity lasers or light-emitting diodes (LEDs) to promote healing and diminish pain and inflammation. For instance, Jaguar Health Inc., an American pharmaceutical enterprise, introduced gelclair, an oral mucositis prescription product, in October 2024. Gelclair is engineered specifically to manage pain linked with oral mucositis, a condition experienced by up to 90% of patients with head and neck cancer undergoing chemotherapy and radiotherapy treatments. Gelclair, which adheres to the mouth's mucosal surface, offers quick and enduring relief from pain without causing the typical stinging or numbing sensations often associated with other treatments.
Who Are the Key Players In The Radiotherapy Induced Oral Mucositis Treatment Market?
Major companies operating in the radiotherapy induced oral mucositis treatment market are:
• Bausch Health Companies Inc.
• Sun Pharmaceutical Industries Ltd.
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Zydus Cadila Health Care Limited
• Leo Pharma A/S
• Glenmark Pharmaceuticals Ltd.
• Almirall S.A.
• Fagron Group BV
• Sage Products LLC
• Soligenix Inc.
• EUSA Pharma Ltd.
• Galera Therapeutics Inc.
• Enzychem Lifesciences Corp.
• Jaguar Health Inc.
• EpicentRx Inc.
• MONOPAR Therapeutics Inc.
• Solasia Pharma KK
• Cellceutix Corporation
• Innovation Pharmaceuticals Inc.
What Are The Regional Insights Into The Radiotherapy Induced Oral Mucositis Treatment Market?
North America was the largest region in the radiotherapy induced oral mucositis treatment market in 2024. The regions covered in the radiotherapy induced oral mucositis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.